Halozyme Therapeutics, Inc. kicked off the trading day on 08/06/19 with a price increase of 1.48%, equivalent to $0.25 relative change for the day. Taking a more long-term approach, HALO had a 52-week range of $13.24 to $18.85. At the time of this article’s publishing, this stock is trading at $17.15 after starting the trading session at $16.99. Moving on, the stock has demonstrated a 52-week change amounting to -2.67, alongside an S&P500 52-Week Change of -8.73. At the time of writing, this stock’s 50-day Moving Average stands at $16.41, while the 200-day Moving Average of this stock is currently $16.10.
Currently, this company’s share volume is sitting at $1,900,302, but has maintained average daily volume of $879.59K. This stock has generated an average Year to Date volume of $817669, alongside an average 20-day volume of $755180. This publicly-traded company’s shares outstanding now amounts to $145.47 million, simultaneously with a float of $132.80 million. The organization now has a market capitalization sitting at $2.49 billion.
Halozyme Therapeutics, Inc.(HALO) Ownership Data
Now let’s turn our focus to how large-scale investors are behaving with this stock. Halozyme Therapeutics, Inc.’s current insider ownership accounts for 1.00%, in contrast to 86.70% institutional ownership. According to the most recent latest insider trade that took place on Aug 03 this organization’s SVP, Chief Medical Officer sold 1,328 at the rate of 16.70, making the entire transaction hit 22,178 in total value, affecting insider ownership by 38,584. Preceding that transaction, on Jun 15 Company’s SVP, Chief Financial Officer exercised an option 6,875 at a price of 0.00, making the whole transaction’s value amount to 0. This particular insider is now the holder of 85,370 in total.
If we take a glance at the Ownership summary of Halozyme Therapeutics, Inc.’s stock, 218 Institutional holders make up 81.76% of its total stock ownership. All together, they are the legal holders of 118,973,593 shares, which are valued at about $2,010,653,722 in total. If we focus on the top 3 stockholders for this publicly-traded organization, THIRD SECURITY, LLC owns 14.09 million shares, with VANGUARD GROUP INC in 2nd place owning 13.52 million shares and BLACKROCK INC. in third place with total ownership of 11.7 million shares.
Halozyme Therapeutics, Inc. (HALO) Earnings and Revenue Data
In the latest quarterly report that this company released, which was put into the public domain on Mar-19, the organization reported $0.01 earnings per share (EPS) for the three-month period, surpassing the consensus estimate (set at $0.01) by $0.00.
The corporation racked up revenue of $60.23million for the previous financial quarter, compared to the mean analyst estimate of $59.77 million. This company achieved a net margin of -28.70 while generating a return on equity of -20.13. Halozyme Therapeutics, Inc.’s full-quarter revenue increased by 84.48%, when compared against the year-ago quarter. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.14 per share during the current fiscal year.
Halozyme Therapeutics, Inc.’s EPS decrease for this current 12-month fiscal period is -223.50%, and is forecasted to reach -2.40% in the upcoming year.
Additional Trading Performance Indicators
Now turning our attention to the current performance indicators for Halozyme Therapeutics, Inc., this organization’s Quick Ratio in the last reported quarter now stands at 2.70. The company has managed to achieve an average true range (ATR) of 0.41. Alongside those, its Beta score is 1.81.
Another valuable indicator worth considering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 14.02 for this organization. Plus, this company’s price to book ratio for the last three-month fiscal period reported is 9.53, whereas its price to cash per share for the last quarter landed at 2.26.
In the same vein, HALO’s Diluted EPS (Earnings per Share) trailing twelve month was posted at -0.36, a figure that is expected to reach -0.14 in the next reported quarter, and analysts expect it will be -2.40% at the market close of one year from today’s date.